2020
DOI: 10.1007/s00213-020-05677-8
|View full text |Cite
|
Sign up to set email alerts
|

Coadministration of metformin prevents olanzapine-induced metabolic dysfunction and regulates the gut-liver axis in rats

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
9
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 14 publications
(10 citation statements)
references
References 47 publications
1
9
0
Order By: Relevance
“…Cassano et al ( Cassano et al, 2020 ) demonstrated that compared with the control group receiving a normal diet of rats, there was no statistical difference in the effect of metformin on blood glucose levels. And Luo et al (2021) reported that after a daily intragastric administration of 500 mg/kg metformin for 35 days, there was no changes in blood glucose in rats, compared with the control group. We treated the rats with metformin at 100, 200, and 400 mg/kg/day for another 28 days.…”
Section: Discussionmentioning
confidence: 99%
“…Cassano et al ( Cassano et al, 2020 ) demonstrated that compared with the control group receiving a normal diet of rats, there was no statistical difference in the effect of metformin on blood glucose levels. And Luo et al (2021) reported that after a daily intragastric administration of 500 mg/kg metformin for 35 days, there was no changes in blood glucose in rats, compared with the control group. We treated the rats with metformin at 100, 200, and 400 mg/kg/day for another 28 days.…”
Section: Discussionmentioning
confidence: 99%
“…The research flora focused on lactobacillus helveticus and probiotic bifidobacterium, while the modeling method concentrated on the high-fat diet ( McKernan et al, 2010 ; Ohland et al, 2013 ; Ait-Belgnaoui et al, 2014 ; Kang et al, 2014 ; Mayer et al, 2014 ; Liang et al, 2015 ; Magnusson et al, 2015 ; Guillemot-Legris et al, 2016 ; Baker et al, 2017 ; Li et al, 2018 ; Schachter et al, 2018 ; Hassan et al, 2019 ; Beraldi et al, 2020 ). After 2015, the main diseases studied were functional gastrointestinal disorders, stress response, ulcerative colitis, prenatal stress, schizophrenia, and mental disorders ( Daulatzai, 2015 ; Schmidt et al, 2015 ; Davis et al, 2016 ; Evrensel and Ceylan, 2016 ; Gur et al, 2017 , 2019 ; Abautret-Daly et al, 2018 ; Jasarevic et al, 2018 ; Ju et al, 2020 ; Bioque et al, 2021 ; Luo et al, 2021 ; Yanguas-Casas et al, 2021 ; Urbonaite et al, 2022 ). Brain-derived neurotrophic factors and Toll-like receptors were the key research factors ( Zeraati et al, 2019 ; Haghighat et al, 2021 ).…”
Section: Discussionmentioning
confidence: 99%
“…62 Recently, metformin treatment was found to reverse olanzapine-induced metabolic alterations (increased body weight, serum glucose, triglycerides, LDL, and decreased HDL levels) and gut dysbiosis (increase in the Firmicutes: Bacteroidetes ratio) in rats. 61 Taken together, these preclinical findings further support the interplay of the GMB and AIMA. Literature search and selection process of included studies.…”
Section: Preclinical Evidence -Gmb and Scz (Table A)mentioning
confidence: 59%